The structure of aggrecan fragments in human synovial fluid. evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis
Open Access
- 1 September 1993
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 36 (9) , 1214-1222
- https://doi.org/10.1002/art.1780360906
Abstract
Objective. To determine the proteolytic fragmentation patterns and N-terminal sequence of aggrecan fragments in human synovial fluid from patients with inflammatory arthritides, joint injury, or osteoarthritis (OA). Methods. Knee synovial fluid was obtained from patients with joint injury, OA, acute pyrophosphate arthritis (pseudogout), reactive arthritis, psoriatic arthritis, or juvenile rheumatoid arthritis. Chondroitin sulfate–substituted aggrecan fragments present in the fluid were purified by cesium chloride gradient centrifugation and enzymatically deglycosylated. Core protein species were determined by N-terminal analysis and by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) with electroblotting and detection with monoclonal antibody 3B3. Results. Samples from patients with joint injury, OA, and inflammatory joint disease all showed a similar 3-band pattern, with core sizes of approximately 200 kd, 170 kd, and 135 kd. In all samples, diffuse immuno-reactive products were also seen, with an apparent size of >250 kd. N-terminal analysis of core preparations of all samples showed a consistent single predominant sequence, beginning at alanine 374 of the human aggrecan core protein. Conclusion. The aggrecan fragments present in joint fluids from patients with various inflammatory arthritides, joint injury, or OA result from a predominant cleavage of the human aggrecan core protein at the glutamate 373–alanine 374 bond within the interglobular domain, between the G1 and G2 domains. The consistent pattern of fragments seen on SDS-PAGE and the single predominant N-terminal sequence suggest a common degradative mechanism of aggrecan in these different joint conditions. The identity of the proteolytic agent (aggrecanase), however, remains unknown. These results appear to have important implications with regard to the development of therapies to protect cartilage from degradation in patients with joint disease.Keywords
This publication has 28 references indexed in Scilit:
- Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritisArthritis & Rheumatism, 1993
- Synovial fluid analysis of two groups of proteoglycan epitopes distinguishes early and late cartilage lesionsArthritis & Rheumatism, 1992
- Detection of Stromelysin and Collagenase in Synovial Fluid From Patients with Rheumatoid Arthritis and Posttraumatic Knee InjuryArthritis & Rheumatism, 1992
- Markers of cartilage metabolism in arthrosisActa Orthopaedica, 1991
- Biochemical demonstration of calpains and calpastatin in osteoarthritic synovial fluidArthritis & Rheumatism, 1990
- Increased levels of proteoglycan fragments in knee joint fluid after injuryArthritis & Rheumatism, 1989
- Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage.Journal of Clinical Investigation, 1989
- Recombinant human interleukin-1 stimulates human articular cartilage to undergo resorption and human chondrocytes to produce both tissue- and urokinase-type plasminogen activatorBiochimica et Biophysica Acta (BBA) - General Subjects, 1988
- Proteoglycan concentration in synovial fluid: predictor of future cartilage destruction in rheumatoid arthritis?BMJ, 1987
- Cartilage proteoglycans in synovial fluid and serum in patients with inflammatory joint disease. relation to systemic treatmentArthritis & Rheumatism, 1987